Insmed Inc. Daily Stock Analysis

Daily Stock Analysis, INSM, Insmed Inc, priceseries

Insmed Inc. Daily Stock Analysis
Stock Information
Open
23.02
Close
23.16
High
23.84
Low
22.97
Previous Close
22.94
Daily Price Gain
0.22
YTD High
28.74
YTD High Date
Jan 4, 2022
YTD Low
20.02
YTD Low Date
Jan 28, 2022
YTD Price Change
-4.97
YTD Gain
-17.67%
52 Week High
41.77
52 Week High Date
Mar 9, 2021
52 Week Low
20.02
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-15.76
52 Week Gain
-40.49%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 17. 2017
17.23
May 3. 2017
18.18
12 Trading Days
5.54%
Link
LONG
Jun 19. 2017
15.97
Jun 30. 2017
17.21
9 Trading Days
7.74%
Link
LONG
Nov 2. 2017
27.92
Nov 17. 2017
30.35
11 Trading Days
8.69%
Link
LONG
Aug 2. 2018
28.08
Aug 3. 2018
29.83
1 Trading Days
6.23%
Link
LONG
Jan 4. 2019
14.85
Feb 21. 2019
25.28
32 Trading Days
70.25%
Link
LONG
Mar 29. 2019
29.07
Apr 17. 2019
30.61
13 Trading Days
5.30%
Link
LONG
Nov 12. 2019
18.99
Dec 27. 2019
23.70
31 Trading Days
24.80%
Link
LONG
Apr 17. 2020
19.33
May 28. 2020
25.29
28 Trading Days
30.82%
Link
LONG
Sep 14. 2020
30.35
Sep 30. 2020
31.95
12 Trading Days
5.27%
Link
LONG
Nov 10. 2020
34.92
Dec 7. 2020
39.31
18 Trading Days
12.56%
Link
LONG
Aug 23. 2021
25.31
Sep 10. 2021
27.16
13 Trading Days
7.33%
Link
LONG
Oct 28. 2021
29.59
Nov 10. 2021
31.65
9 Trading Days
6.97%
Link
Company Information
Stock Symbol
INSM
Exchange
NasdaqGS
Company URL
http://www.insmed.com
Company Phone
908-977-9900
CEO
Will Lewis
Headquarters
New Jersey
Business Address
10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER, NJ 08807
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001104506
About

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.

Description

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading